Richard Cheng
University of Washington
Internal medicineSurgeryCardiologyIntensive care medicineCardiogenic shockIntravascular ultrasoundHeart failureCoronary artery diseaseVentricular assist deviceHeart transplantationDiseasePercutaneous coronary interventionPopulationCardiac allograft vasculopathyTransplantationMitral regurgitationIn patientMyocardial infarctionMedicineEjection fraction
Publications 177
#1Parvathi Mudigonda (UW: University of Washington)
#2Cecilia Berardi (UW: University of Washington)
Last. Richard Cheng (UW: University of Washington)H-Index: 19
view all 0 authors...
Cancer and cardiovascular disease share many risk factors. Due to improved survival of patients with cancer, the cohort of cancer survivors with heart failure referred for heart transplantation (HT) is growing. Specific considerations include time interval between cancer treatment and HT, risk for recurrence and risk for de novo malignancy (dnM). dnM is an important cause of post-HT morbidity and mortality, with nearly a third diagnosed with malignancy by 10 years post-HT. Compared with the age-...
#1Rudolf A. de Boer (UMCG: University Medical Center Groningen)H-Index: 88
#2Joseph Pierre Aboumsallem (UMCG: University Medical Center Groningen)H-Index: 3
Last. Jennifer M. Kwan (Yale University)H-Index: 11
view all 0 authors...
Increasing evidence suggests a multifaceted relationship exists between cancer and cardiovascular disease (CVD). Here, we introduce a 5-tier classification system to categorize cardio-oncology syndromes (COS) that represent the aspects of the relationship between cancer and CVD. COS Type I is characterized by mechanisms whereby the abrupt onset or progression of cancer can lead to cardiovascular dysfunction. COS Type II includes the mechanisms by which cancer therapies can result in acute or chr...
#1Michael G. FradleyH-Index: 14
#2Theresa M. BeckieH-Index: 24
Last. Brian OlshanskyH-Index: 33
view all 0 authors...
With the advent of novel cancer therapeutics and improved screening, more patients are surviving a cancer diagnosis or living longer with advanced disease. Many of these treatments have associated cardiovascular toxicities that can manifest in both an acute and a delayed fashion. Arrhythmias are an increasingly identified complication with unique management challenges in the cancer population. The purpose of this scientific statement is to summarize the current state of knowledge regarding arrhy...
#1Douglas Leedy (University of Washington Medical Center)H-Index: 3
#2Jasleen Tiwana (University of Washington Medical Center)H-Index: 1
Last. Richard Cheng (University of Washington Medical Center)H-Index: 19
view all 0 authors...
Cancer and coronary artery disease (CAD) overlap in traditional risk factors as well as molecular mechanisms underpinning the development of these two disease states. Patients with cancer are at increased risk of developing CAD, representing a high-risk population that are increasingly undergoing coronary revascularisation. Over 1 in 10 patients with CAD that require revascularisation with either percutaneous coronary intervention or coronary artery bypass grafting have either a history of cance...
#1Jan M. Griffin (Columbia University)H-Index: 4
#2Richard Cheng (University of Washington Medical Center)H-Index: 19
Over the last decade, treatment for heart failure with reduced ejection fraction (HFrEF) has advanced, with the incremental addition of novel evidence-based medical therapies. The landmark PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) study showed that the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan was superior to enalapril in reducing risk of death and HF hospitalisations.1 This has paved ...
#1Ilana Schlam (Washington Cancer Institute)H-Index: 2
#1Ilana Schlam (Washington Cancer Institute)H-Index: 4
Last. Richard Cheng (University of Washington Medical Center)H-Index: 19
view all 0 authors...
#1Stephan Schueler (Freeman Hospital)H-Index: 24
#2Scott C. SilvestryH-Index: 26
Last. Claudius Mahr (UW: University of Washington)H-Index: 13
view all 11 authors...
AIMS Continuous-flow left ventricular assist devices (LVADs) as destination therapy (DT) are a recommended treatment by National Institute for Health and Care Excellence England for end-stage heart failure patients ineligible for cardiac transplantation. Despite the fact that DT is frequently used as an LVAD indication across other major European countries and the United States, with consistent improvements in quality-of-life and longevity, National Health Service (NHS) England does not currentl...
#1Neal A. Chatterjee (UW: University of Washington)H-Index: 7
#2Paul N. Jensen (UW: University of Washington)H-Index: 24
Last. Nona Sotoodehnia (UW: University of Washington)H-Index: 64
view all 14 authors...
COVID-19 has significant case fatality. Glucocorticoids are the only treatment shown to improve survival, but only among patients requiring supplemental oxygen. WHO advises patients to seek medical care for "trouble breathing," but hypoxemic patients frequently have no respiratory symptoms. Our cohort study of hospitalized COVID-19 patients shows that respiratory symptoms are uncommon and not associated with mortality. By contrast, objective signs of respiratory compromise-oxygen saturation and ...
#1Doug J Leedy (UW: University of Washington)
#2Kerryn W. Reding (UW: University of Washington)H-Index: 13
Last. Richard Cheng (UW: University of Washington)H-Index: 19
view all 12 authors...
Aims There is conflicting evidence whether heart failure (HF) is a risk factor for incident cancer. Despite population-based cohorts demonstrating this association, an analysis of the Physician's Health Study found no association in a cohort of mostly healthy males. We investigated the association of HF with incident cancer among a large cohort of post-menopausal women. Methods and results A prospective cohort study of 146,817 post-menopausal women age 50 to 79 years enrolled in the Women's Heal...
#1David H. Lam (UW: University of Washington)H-Index: 4
#2Jasleen TiwanaH-Index: 2
Last. Richard ChengH-Index: 19
view all 5 authors...
OBJECTIVE In response to the growing use of imaging-based cardiac stress tests in the evaluation of stable ischemic heart disease, professional societies have developed appropriate use criteria (AUC). AUC will soon be linked to reimbursement of advanced diagnostic imaging for Medicare beneficiaries via Clinical Decision Support Mechanisms (CDSMs). We sought to characterize the frequency and type of stress test utilization for chest pain referrals evaluated by cardiologists and determine appropri...